Limits...
The production of cross-reactive autoantibodies that bind to bovine serum albumin in mice administered reducing sugars by subcutaneous injection.

Park JH, Choi TS - Cent Eur J Immunol (2015)

Bottom Line: However, these autoantibodies did not cross-react with MSA, and simultaneous treatment of aminoguanidine with reducing sugars did not show any inhibitory effects on the formation of autoantibodies.No autoantibodies were detected after oral or intraperitoneal administration of reducing sugars.Our results show that administration of reducing sugars by subcutaneous injection leads to the formation of autoantibodies that cross-react with BSA; the formation and target antigen(s) of the autoantibodies may originate from within the skin tissue treated with the reducing sugars.

View Article: PubMed Central - PubMed

Affiliation: Department of Microbiology, College of Medicine, Dankook University, Cheonan, Korea.

ABSTRACT

Introduction: In a previous study, we identified the formation of cross-reactive autoantibodies that bound to bovine serum albumin (BSA) in a D-galactose-induced aging mouse model.

Aim of the study: In this study, we investigated the effect of other reducing sugars (namely, glucose and fructose) on the formation of autoantibodies. The effects of concentration and route of administration on the formation of autoantibodies were examined in detail.

Material and methods: Three concentrations (100, 500, and 1,000 mg/kg) of reducing sugars were tested. The effects of different routes of administration (subcutaneous, oral, and intraperitoneal) on the formation of autoantibodies were also analysed. The immunoreactivities of serum samples from mice treated with reducing sugars were analysed by an enzyme-linked immunosorbent assay (ELISA) using BSA or mouse serum albumin antigens (MSA).

Results: Repeated subcutaneous administration of all reducing sugars lead to autoantibody formation in a concentration-dependent manner. However, these autoantibodies did not cross-react with MSA, and simultaneous treatment of aminoguanidine with reducing sugars did not show any inhibitory effects on the formation of autoantibodies. No autoantibodies were detected after oral or intraperitoneal administration of reducing sugars. Immunohistochemistry data showed that the target antigen(s) of the autoantibodies were present only in the skin tissue of mice treated with reducing sugars.

Conclusions: Our results show that administration of reducing sugars by subcutaneous injection leads to the formation of autoantibodies that cross-react with BSA; the formation and target antigen(s) of the autoantibodies may originate from within the skin tissue treated with the reducing sugars.

No MeSH data available.


Related in: MedlinePlus

H&E staining and immunohistochemistry of mouse back skin. Mouse back skin around the injection sites was isolated. A) H&E staining at 100× magnification, scale bar = 100 µm. B) Immunostaining at 200× magnification with serum from mice treated with D-gal. Granulation tissue (Gr) was observed beneath the skin muscle layer (M). Immunostaining revealed positive signals, as indicated by brown coloration, in several cell types, including macrophage-like cells, and in the stratum corneum
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4472536&req=5

Figure 0004: H&E staining and immunohistochemistry of mouse back skin. Mouse back skin around the injection sites was isolated. A) H&E staining at 100× magnification, scale bar = 100 µm. B) Immunostaining at 200× magnification with serum from mice treated with D-gal. Granulation tissue (Gr) was observed beneath the skin muscle layer (M). Immunostaining revealed positive signals, as indicated by brown coloration, in several cell types, including macrophage-like cells, and in the stratum corneum

Mentions: The strong immunoreactivity observed when the subcutaneous injection of reducing sugar suggested that unknown proteins in the mouse skin functioned as antigens to produce autoantibodies. To investigate this, H&E staining and immunohistochemical analyses were performed using the autoantibody on mouse skin tissues. Haematoxylin and eosin staining showed localisation of granulation tissue beneath the muscle layers and infiltration of immune cells, especially in mouse skin treated with reducing sugars (Fig. 4A). The immunohistochemical analysis showed autoantibody reactivity by some cell types, including macrophage-like cells, and the stratum corneum in skin tissues treated with reducing sugars (Fig. 4B).


The production of cross-reactive autoantibodies that bind to bovine serum albumin in mice administered reducing sugars by subcutaneous injection.

Park JH, Choi TS - Cent Eur J Immunol (2015)

H&E staining and immunohistochemistry of mouse back skin. Mouse back skin around the injection sites was isolated. A) H&E staining at 100× magnification, scale bar = 100 µm. B) Immunostaining at 200× magnification with serum from mice treated with D-gal. Granulation tissue (Gr) was observed beneath the skin muscle layer (M). Immunostaining revealed positive signals, as indicated by brown coloration, in several cell types, including macrophage-like cells, and in the stratum corneum
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4472536&req=5

Figure 0004: H&E staining and immunohistochemistry of mouse back skin. Mouse back skin around the injection sites was isolated. A) H&E staining at 100× magnification, scale bar = 100 µm. B) Immunostaining at 200× magnification with serum from mice treated with D-gal. Granulation tissue (Gr) was observed beneath the skin muscle layer (M). Immunostaining revealed positive signals, as indicated by brown coloration, in several cell types, including macrophage-like cells, and in the stratum corneum
Mentions: The strong immunoreactivity observed when the subcutaneous injection of reducing sugar suggested that unknown proteins in the mouse skin functioned as antigens to produce autoantibodies. To investigate this, H&E staining and immunohistochemical analyses were performed using the autoantibody on mouse skin tissues. Haematoxylin and eosin staining showed localisation of granulation tissue beneath the muscle layers and infiltration of immune cells, especially in mouse skin treated with reducing sugars (Fig. 4A). The immunohistochemical analysis showed autoantibody reactivity by some cell types, including macrophage-like cells, and the stratum corneum in skin tissues treated with reducing sugars (Fig. 4B).

Bottom Line: However, these autoantibodies did not cross-react with MSA, and simultaneous treatment of aminoguanidine with reducing sugars did not show any inhibitory effects on the formation of autoantibodies.No autoantibodies were detected after oral or intraperitoneal administration of reducing sugars.Our results show that administration of reducing sugars by subcutaneous injection leads to the formation of autoantibodies that cross-react with BSA; the formation and target antigen(s) of the autoantibodies may originate from within the skin tissue treated with the reducing sugars.

View Article: PubMed Central - PubMed

Affiliation: Department of Microbiology, College of Medicine, Dankook University, Cheonan, Korea.

ABSTRACT

Introduction: In a previous study, we identified the formation of cross-reactive autoantibodies that bound to bovine serum albumin (BSA) in a D-galactose-induced aging mouse model.

Aim of the study: In this study, we investigated the effect of other reducing sugars (namely, glucose and fructose) on the formation of autoantibodies. The effects of concentration and route of administration on the formation of autoantibodies were examined in detail.

Material and methods: Three concentrations (100, 500, and 1,000 mg/kg) of reducing sugars were tested. The effects of different routes of administration (subcutaneous, oral, and intraperitoneal) on the formation of autoantibodies were also analysed. The immunoreactivities of serum samples from mice treated with reducing sugars were analysed by an enzyme-linked immunosorbent assay (ELISA) using BSA or mouse serum albumin antigens (MSA).

Results: Repeated subcutaneous administration of all reducing sugars lead to autoantibody formation in a concentration-dependent manner. However, these autoantibodies did not cross-react with MSA, and simultaneous treatment of aminoguanidine with reducing sugars did not show any inhibitory effects on the formation of autoantibodies. No autoantibodies were detected after oral or intraperitoneal administration of reducing sugars. Immunohistochemistry data showed that the target antigen(s) of the autoantibodies were present only in the skin tissue of mice treated with reducing sugars.

Conclusions: Our results show that administration of reducing sugars by subcutaneous injection leads to the formation of autoantibodies that cross-react with BSA; the formation and target antigen(s) of the autoantibodies may originate from within the skin tissue treated with the reducing sugars.

No MeSH data available.


Related in: MedlinePlus